相似文献
1
Crystal structures of HIV-1 reverse transcriptase with picomolar inhibitors reveal key interactions for drug design.
J Am Chem Soc. 2012 Dec 5;134(48):19501-3. doi: 10.1021/ja3092642. Epub 2012 Nov 19.
2
Structure-based evaluation of C5 derivatives in the catechol diether series targeting HIV-1 reverse transcriptase.
Chem Biol Drug Des. 2014 May;83(5):541-9. doi: 10.1111/cbdd.12266. Epub 2014 Mar 14.
3
The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.
J Mol Biol. 2001 Jun 1;309(2):437-45. doi: 10.1006/jmbi.2001.4648.
4
Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance.
J Mol Biol. 1998 Nov 27;284(2):313-23. doi: 10.1006/jmbi.1998.2171.
5
Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
J Med Chem. 2012 Dec 13;55(23):10601-9. doi: 10.1021/jm301294g. Epub 2012 Nov 26.
6
Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.
J Mol Biol. 1996 Dec 20;264(5):1085-100. doi: 10.1006/jmbi.1996.0698.
7
Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants.
J Med Chem. 2015 Mar 26;58(6):2737-45. doi: 10.1021/jm501908a. Epub 2015 Mar 5.
8
Halogen bonding for rational drug design and new drug discovery.
Expert Opin Drug Discov. 2012 May;7(5):375-83. doi: 10.1517/17460441.2012.678829. Epub 2012 Mar 30.
9
Synthesis and biological evaluation of novel C5 halogen-functionalized S-DABO as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
Bioorg Med Chem. 2010 May 1;18(9):3231-7. doi: 10.1016/j.bmc.2010.03.025. Epub 2010 Mar 15.
10
Halogen bonding in halocarbon-protein complexes: a structural survey.
Chem Soc Rev. 2011 May;40(5):2267-78. doi: 10.1039/c0cs00177e. Epub 2011 Mar 1.
引用本文的文献
1
Advancing Covalent Ligand and Drug Discovery beyond Cysteine.
Chem Rev. 2025 Jul 23;125(14):6653-6684. doi: 10.1021/acs.chemrev.5c00001. Epub 2025 May 22.
2
Structure-based design and optimization lead to the identification of novel dihydrothiopyrano[3,2-]pyrimidine derivatives as potent HIV-1 inhibitors against drug-resistant variants.
Acta Pharm Sin B. 2024 Mar;14(3):1257-1282. doi: 10.1016/j.apsb.2023.11.023. Epub 2023 Nov 24.
3
Strategies in the Design and Development of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs).
Viruses. 2023 Sep 25;15(10):1992. doi: 10.3390/v15101992.
4
Design, synthesis, and biological testing of biphenylmethyloxazole inhibitors targeting HIV-1 reverse transcriptase.
Bioorg Med Chem Lett. 2023 Mar 15;84:129216. doi: 10.1016/j.bmcl.2023.129216. Epub 2023 Mar 3.
5
New Derivatives of 5-Substituted Uracils: Potential Agents with a Wide Spectrum of Biological Activity.
Molecules. 2022 Apr 30;27(9):2866. doi: 10.3390/molecules27092866.
6
Structural Studies and Structure Activity Relationships for Novel Computationally Designed Non-nucleoside Inhibitors and Their Interactions With HIV-1 Reverse Transcriptase.
Front Mol Biosci. 2022 Feb 14;9:805187. doi: 10.3389/fmolb.2022.805187. eCollection 2022.
7
Long-acting and extended-release implant and nanoformulations with a synergistic antiretroviral two-drug combination controls HIV-1 infection in a humanized mouse model.
Bioeng Transl Med. 2021 Jun 26;7(1):e10237. doi: 10.1002/btm2.10237. eCollection 2022 Jan.
8
The Fellowship of Privileged Scaffolds-One Structure to Inhibit Them All.
Pharmaceuticals (Basel). 2021 Nov 16;14(11):1164. doi: 10.3390/ph14111164.
9
Covalent Inhibition of Wild-Type HIV-1 Reverse Transcriptase Using a Fluorosulfate Warhead.
ACS Med Chem Lett. 2021 Jan 6;12(2):249-255. doi: 10.1021/acsmedchemlett.0c00612. eCollection 2021 Feb 11.
10
Evolving understanding of HIV-1 reverse transcriptase structure, function, inhibition, and resistance.
Curr Opin Struct Biol. 2020 Apr;61:113-123. doi: 10.1016/j.sbi.2019.11.011. Epub 2020 Jan 11.
本文引用的文献
1
Treatment of Halogen Bonding in the OPLS-AA Force Field; Application to Potent Anti-HIV Agents.
J Chem Theory Comput. 2012 Oct 9;8(10):3895-3801. doi: 10.1021/ct300180w. Epub 2012 Apr 3.
2
Discovery of dimeric inhibitors by extension into the entrance channel of HIV-1 reverse transcriptase.
Bioorg Med Chem Lett. 2012 Feb 15;22(4):1565-8. doi: 10.1016/j.bmcl.2011.12.132. Epub 2012 Jan 5.
3
Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.
J Med Chem. 2011 Dec 22;54(24):8582-91. doi: 10.1021/jm201134m. Epub 2011 Nov 29.
4
Systematic investigation of halogen bonding in protein-ligand interactions.
Angew Chem Int Ed Engl. 2011 Jan 3;50(1):314-8. doi: 10.1002/anie.201006781.
5
Halogen bonding: an electrostatically-driven highly directional noncovalent interaction.
Phys Chem Chem Phys. 2010 Jul 28;12(28):7748-57. doi: 10.1039/c004189k. Epub 2010 Jun 22.
6
Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses.
Bioorg Med Chem Lett. 2010 Jul 15;20(14):4215-8. doi: 10.1016/j.bmcl.2010.05.040. Epub 2010 May 16.
7
Phaser crystallographic software.
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674. doi: 10.1107/S0021889807021206. Epub 2007 Jul 13.
8
Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design.
Nucleic Acids Res. 2008 Sep;36(15):5083-92. doi: 10.1093/nar/gkn464. Epub 2008 Aug 1.
9
High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations.
Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1466-71. doi: 10.1073/pnas.0711209105. Epub 2008 Jan 29.
10
Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses.
Protein Sci. 2007 Aug;16(8):1728-37. doi: 10.1110/ps.072829007.
Zotero 插件